Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Intracameral dexamethasone for hard cataract surgery with topical anesthesia: improving patient comfort

Poster Details

First Author: E. Sanz-Marco SPAIN

Co Author(s):    A. Hervas-Ontiveros   S. Garcia-Delpech   D. Salom-Alonso              

Abstract Details


To analyze effectiveness and safety of intracameral dexamethasone in hard cataract surgery using topical anesthesia.


Study was carried out in Manises Hospital in Valencia, Spain.


14 patients with hard cataract who underwent cataract surgery with topical anesthesia were included. Visthesia® (1.5% sodium hyaluronate and 2.0% lidocaine hydrochloride) was used during surgery, and dispersive viscoelastic, Z-Hyalcoat® (3% sodium hyaluronate) was used prior to phacoemulsification. 0.1ml intracameral dexamethasone was administered at the end of the cataract surgery prior to 0.1ml intracameral cefuroxime administration. No prophylactic intraocular pressure-lowering medication was used. Main outcomes were: best corrected visual acuity (BCVA), presence of corneal edema and intraocular pressure (IOP). Data were collected one day after surgery, one week after surgery and one month after surgery.


No increased intraocular pressure was observed during the follow-up, highest IOP registered was 25mmHg one day after surgery. Mean IOP was 18.21±3.70mmHg one day after surgery, 13.29±2.57mmHg one week after surgery and 13.50±2.57mmHg one month after surgery. 3 patients presented corneal edema one day after surgery, 2 patients one week after surgery, no patients presented corneal edema one month after surgery. Mean BCVA one month after surgery was 0.54±0.08.


Intracameral dexamethasone is a safe, painless and effective alternative to subconjuntival or sub-Tenon injection of corticosteroids. More studies are needed to corroborate our conclusions.

Financial Disclosure:


Back to Poster listing